第四条 公司委托理财的资金为闲置自有资金、闲置募集资金（仅可用于现金 管理的委托理财），不得挤占公司正常运营和项目建设资金，不得影响募集资金项 目使用进度。 第五条 公司委托理财坚持"规范运作、防范风险、谨慎投资、保值增值"的 原则，应遵守如下规定： 广东正业科技股份有限公司 委托理财管理制度 第一章 总 则 第一条 为规范广东正业科技股份有限公司（以下简称"公司"）委托理财行 为，有效控制投资风险，保证公司资产、财产的安全，提高投资收益，维护公司 及股东的合法权益，根据《中华人民共和国公司法》、《深圳证券交易所创业板股票 上市规则》、《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司 规范运作》、《深圳证券交易所上市公司自律监管指引第 7 号——交易与关联交 易》等有关法律、行政法规、部门规章、规范性文件及《公司章程》的规定，结 合公司实际情况，制定本制度。 第二条 本制度所称"委托理财"是指在国家政策允许的情况下，在控制投资 风险的前提下，以提高资金使用效率、增加现金资产收益为原则，公司委托银 行、信托、证券、基金、期货、保险资产管理机构、金融资产投资公司、私募基 金管理人等专业理财机构对公 ...

证券代码：300410 证券简称：正业科技 公告编号：2026-009 广东正业科技股份有限公司 关于日常经营合同的自愿性信息披露公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、合同的生效条件：本合同经双方签字或盖章之日起生效。 2、合同的风险及不确定性：合同履行过程中，可能面临政策调整、市场环 境、客户需求、技术变化及其他不可预见或不可抗力等因素影响合同最终执行情 况的风险。敬请广大投资者谨慎决策，注意投资风险。 3、合同履行对公司本年度经营成果的影响：本合同的履行，预计对公司本 年度经营业绩无重大影响，将对公司未来经营业绩产生积极影响，具体影响金额 及影响的报告期最终将以公司经审计的财务数据为准。 一、合同签署概况 近日，广东正业科技股份有限公司（以下简称"公司"）与苏州正力新能电 池科技有限公司（以下简称"苏州正力"）签订了《购销合同》，苏州正力向公 司采购数台离线 X-ray 检测机和 X-ray 检测机，合同金额为人民币 66,421,400.00 元（含税）。上述合同属于公司日常经营合同，根据《深圳证券交易所创业板股 票上市规 ...

证券代码：300410 证券简称：正业科技 公告编号：2026-008 广东正业科技股份有限公司 关于为全资孙公司提供担保的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、对外担保的审批程序 广东正业科技股份有限公司（以下简称"公司"）于 2025 年 4 月 23 日召开 第六届董事会第四次会议，于 2025 年 5 月 16 日召开 2024 年年度股东大会审议 通过了《关于 2025 年度对外担保额度预计的议案》。根据合并报表范围内的公 司业务发展的需要，公司及子公司拟为合并报表范围内的公司 2025 年度预计提 供担保额度合计 30,155 万元，其中为孙公司江苏正业智造技术有限公司（以下 简称"江苏正业"）新增担保额度人民币 4,000 万元。本次担保额度有效期自 2024 年年度股东大会审议通过之日起至 2025 年年度股东大会重新审议为合并报 表范围内的公司提供担保事项的决策程序生效之日止。在 2025 年度预计担保总 额度及期限内，授权公司董事长或总经理及其授权代表全权负责相关业务审批、 办理及相关协议、合同等法律文件签署等事宜。 ...

Group 1: Company Overview - The companies mentioned are "Zhengye Technology" (300410) and "Yifang Bio" (688382), both of which have names related to "bio" and sound similar to "Zhengye" [1] Group 2: Stock Performance - As of January 25, 2026, Yifang Bio's stock price increased by 5.29% during that week, although there was a net outflow of main funds [2] Group 3: Financial Performance - Yifang Bio's Q3 2025 report indicated that both revenue and net profit grew year-on-year for the first three quarters [3] - Despite the growth in revenue, the company reported a negative net profit for the first three quarters of 2025, as it remains in the research and development investment phase [5] Group 4: Recent Developments - Yifang Bio has initiated an "A+H" share listing plan, having submitted a listing application to the Hong Kong Stock Exchange on January 1, 2026 [4] - The company has received approval for two innovative drugs, which have been included in the national medical insurance catalog [5]

Core Viewpoint - The article analyzes the 2025 performance forecasts of 22 domestic listed instrument companies, highlighting the divergence in performance and the impact of various market factors on the industry [2]. Group 1: Industry Overview - The overall operating conditions of the domestic instrument industry are gradually becoming clearer as companies disclose their 2025 performance forecasts [2]. - Among the 22 companies, 11 reported profits while 11 incurred losses; 8 of the profitable companies experienced year-on-year growth, while 3 saw stable or slightly fluctuating profits [2]. - The performance divergence is attributed to factors such as fluctuations in downstream demand, intensified industry competition, policy changes, and global supply chain instability [2]. Group 2: Performance Statistics - The net profit statistics for the listed instrument companies indicate significant growth for several firms, with some achieving over 190% year-on-year increases [3][8]. - Notable performers include: - Aiko Optoelectronics: Net profit of 0.57-0.7 billion, up 262.52-345.20% from 0.1572 billion [3]. - Haineng Technology: Net profit of 0.41-0.44 billion, up 213.65-236.61% from 0.1307 billion [3]. - Wan Yi Technology: Net profit of 0.42-0.62 billion, up 191.52-330.34% from 0.1441 billion [3]. Group 3: Industry Trends - The industry is witnessing increased performance divergence, with a trend towards higher concentration as companies with core technologies and strategic layouts capture more market share [5]. - The ongoing domestic substitution is deepening, with high-end instruments becoming a key growth driver, supported by policy incentives for high-end scientific instruments and equipment upgrades [5]. - Companies focusing on high-end sectors, such as high-end industrial imaging and clinical diagnostics, are expected to benefit from these trends [5]. Group 4: Operational Strategies - Companies facing operational pressures are likely to improve performance by divesting loss-making businesses, optimizing asset structures, and enhancing management of receivables and inventory [6]. - Profit-making companies will continue to pursue refined management practices to consolidate their advantages and enhance risk resilience [6]. Group 5: Performance Categories - Companies achieving profit growth or turning losses into profits are primarily benefiting from asset impairment improvements and business structure optimizations [18]. - The companies in this category include: - Gaode Infrared: Successfully turned around from a loss to a profit [18]. - Xianhe Environmental: Achieved profitability through structural optimization [21]. - Zhengye Technology: Also turned from loss to profit due to similar improvements [22]. Group 6: Challenges Faced - Companies experiencing expanded losses or transitioning from profit to loss share common challenges, including reliance on single business lines and significant asset impairment pressures [30]. - The need for transformation is evident, as some companies are in the process of adjusting their business models, which may not yet yield sufficient revenue to offset declines in traditional business areas [30].

Core Viewpoint - Zhengye Technology (300410) announced that as of the date of the announcement, the company and its subsidiaries do not have overdue guarantees, other litigation-related guarantee amounts, or losses incurred due to guarantee judgments [1] Group 1 - The company confirmed the absence of overdue guarantees [1] - There are no ongoing litigations related to guarantees [1] - The company has not incurred any losses from guarantee-related judgments [1]

本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 证券代码：300410 证券简称：正业科技 公告编号：2026-007 广东正业科技股份有限公司 关于为全资子公司提供担保的进展公告 一、对外担保的审批程序 广东正业科技股份有限公司（以下简称"公司"）于 2025 年 4 月 23 日召开 第六届董事会第四次会议，于 2025 年 5 月 16 日召开 2024 年年度股东大会审议 通过了《关于 2025 年度对外担保额度预计的议案》。根据合并报表范围内的公 司业务发展的需要，公司及子公司拟为合并报表范围内的公司 2025 年度预计提 供担保额度合计 30,155 万元，其中为子公司深圳市集银科技有限公司（以下简 称"集银科技"）新增担保额度人民币 5,000 万元。本次担保额度有效期自 2024 年年度股东大会审议通过之日起至 2025 年年度股东大会重新审议为合并报表范 围内的公司提供担保事项的决策程序生效之日止。在 2025 年度预计担保总额度 及期限内，授权公司董事长或总经理及其授权代表全权负责相关业务审批、办理 及相关协议、合同等法律文件签署等事宜。具 ...

Group 1 - The core point of the article is that Zhengye Technology (300410) reported a total of 35,811 shareholders as of January 30, 2026 [1]

证券代码：300410 证券简称：正业科技 公告编号：2026-006 广东正业科技股份有限公司 关于为全资子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、对外担保的审批程序 广东正业科技股份有限公司（以下简称"公司"）于 2025 年 4 月 23 日召开 第六届董事会第四次会议，于 2025 年 5 月 16 日召开 2024 年年度股东大会审议 通过了《关于 2025 年度对外担保额度预计的议案》。根据合并报表范围内的公 司业务发展的需要，公司及子公司拟为合并报表范围内的公司 2025 年度预计提 供担保额度合计 30,155 万元，其中为子公司深圳市鹏煜威科技有限公司（以下 简称"深圳鹏煜威"）新增担保额度人民币 4,000 万元。本次担保额度有效期自 2024 年年度股东大会审议通过之日起至 2025 年年度股东大会重新审议为合并报 表范围内的公司提供担保事项的决策程序生效之日止。在 2025 年度预计担保总 额度及期限内，授权公司董事长或总经理及其授权代表全权负责相关业务审批、 办理及相关协议、合同等法律文件签署等事宜 ...

Core Viewpoint - The company expects a net profit of 32.5 million to 40 million yuan for the fiscal year 2025, a significant improvement from a net loss of 222.3 million yuan in the same period last year [1] Financial Performance - The projected net profit for 2025 is between 32.5 million and 40 million yuan [1] - The previous year's net profit was a loss of 222.3 million yuan [1] Strategic Measures - The company continues to implement a series of loss-reduction measures for related loss-making subsidiaries, effectively mitigating the negative impact of loss-making businesses [1]